Cotinga Pharmaceuticals IPO year
What is the IPO year of Cotinga Pharmaceuticals?
The IPO year of Cotinga Pharmaceuticals, Inc. is 2007
What is the definition of IPO year?
Initial public offering is a type of public offering in which shares of a company usually are sold to institutional investors that in turn, sell to the general public, on a securities exchange, for the first time.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO year of companies in the Health Care sector on TSXV compared to Cotinga Pharmaceuticals
What does Cotinga Pharmaceuticals do?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Companies with ipo year similar to Cotinga Pharmaceuticals
- G3 Exploration has IPO year of 2006
- Evolis SA has IPO year of 2006
- Unity Infraprojects has IPO year of 2006
- News Invest has IPO year of 2006
- AuStar Gold has IPO year of 2006
- Sky and Space Global has IPO year of 2006
- Cotinga Pharmaceuticals has IPO year of 2007
- Manas Resources has IPO year of 2008
- Mastech Digital Inc has IPO year of 2008
- MYR Inc has IPO year of 2008
- Dana Inc has IPO year of 2008
- American Water Works Co has IPO year of 2008
- Chromadex Corp has IPO year of 2008